Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

scientific article published on 13 March 2012

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/10428194.2011.631236
P698PubMed publication ID21988665

P50authorL Jeffrey MedeirosQ87358453
Jorge RomagueraQ88022461
Anas YounesQ91632799
Michelle A FanaleQ96200428
Luis E. FayadQ106561774
Yasuhiro OkiQ114427964
Amanda R CopelandQ114726224
Silvana de Castro FariaQ114726255
P2093author name stringPercy Ivy
P433issue5
P304page(s)990-992
P577publication date2012-03-13
P1433published inLeukemia & LymphomaQ6534493
P1476titleClinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma
P478volume53

Reverse relations

cites work (P2860)
Q4119799717AAG-induced internalisation of HER2-specific Affibody molecules
Q36162351Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
Q42384507Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma
Q35057071Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux
Q26778944Hsp90: A New Player in DNA Repair?
Q39074963No stress--Hsp90 and signal transduction in Leishmania

Search more.